Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2026-04-23 @ 10:20 PM
Study NCT ID:
NCT02642094
Status:
TERMINATED
Last Update Posted:
2023-12-05
First Post:
2015-11-25
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Aging Mammary Stem Cells and Breast Cancer Prevention
Sponsor:
LuZhe Sun
Organization:
Study Overview
Official Title:
Aging Mammary Stem Cells and Breast Cancer Prevention
Status:
TERMINATED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was terminated early according to the protocol due to efficacy.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens
Detailed Description:
A non-randomized, open-label, phase II, window of opportunity trial will be carried out to see if a 5-7 day rapamycin treatment can reduce malignant markers and aberrant MaSC number
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 1R01CA192564-01A1 | NIH | None | https://reporter.nih.gov/quic… | View |